Kazia Therapeutics Limited (KZIA) — RQD Stock Rating Cockpit

The Roarable RQD rating is 61, graded C- and labeled "Roarable Hold — Cautious Neutral," per the Roarable RQD rating. Across its five pillars:

• Fundamental Cash Engine (12 / 20): Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the cash-generation pillar is the weakest of the fundamental inputs in the rating: the source data shows no return on invested capital and no free-cash-flow yield to anchor valuation.
• Whale 13F Flow (12 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying 13F and options detail is not itemized in the source data, so the score can be read as moderate institutional interest without the specifics behind it.
• Insider Conviction (9 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest pillar score, suggesting insider and congressional activity provides limited conviction support in this rating.
• Macro Regime Fit (15 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity. A beta of 1.0 implies market-matching sensitivity to broad moves, which is a neutral macro posture rather than a defensive or aggressive one.
• Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. These are the strongest pillar inputs and indicate a balance sheet that is more stable than the cash-generation pillar alone would suggest.

Taken together, the rating frames KZIA as a stock where balance-sheet forensics are the most supportive element, while cash generation and insider conviction are the weakest. Valuation tradeoffs cannot be assessed directly because P/E, EV/EBITDA, and EPS are not available in source data, so upside claims must be weighed against the absence of earnings-based valuation anchors.

Kazia Therapeutics Limited (KZIA) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the company profile. Its market capitalization is $0.1B per the company profile. Products sold, customer base, and revenue model are not available in source data.

• Green catalysts: A TradingView report (per the news feed) carries the headline "Kazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% Upside" (flagged GREEN, CATALYST). A Benzinga report flags a bullish analyst initiation (GREEN, CATALYST). A Seeking Alpha report notes Guggenheim starting coverage at Buy (GREEN, CATALYST).
• Yellow market-wire items: A StockInvest.us forecast piece (YELLOW, MARKET WIRE) and a MarketScreener notice that 5,713,449,734 Ordinary Shares are subject to a Lock-Up Agreement ending 28-OCT-2026 (YELLOW, MARKET WIRE).
• Red risk-watch item: A Stock Titan report that a live webcast will carry Kazia executives' Nov. 9 conference chat (RED, RISK WATCH). The feed labels this as risk-watch, but the headline itself does not state the nature of the risk.
• Proprietary signals: None. The Butterfly Supply-Chain Graph lists no butterfly links and no proprietary signals.

The lock-up expiry on 28-OCT-2026 is noteworthy relative to the data date of 2026-11-02, as it falls before the as-of date.

Per the Butterfly Supply-Chain Graph, supply chain is "NONE" and there are no butterfly links. Upstream and downstream dependencies, sector correlations beyond the Health Care classification, and second-order bottlenecks are not available in source data. The one ripple-relevant item is the large lock-up share count noted in the news feed; the scale of that overhang relative to the $0.1B market capitalization is a second-order consideration for float and supply of shares.

• What are the reported revenue, earnings, and cash-flow figures behind the 0% margins and ROIC cited in the RQD rating?
• Which specific 13F holders and options positions underlie the 12 / 20 whale-flow pillar score?
• What is the composition and identity of the insider Form 4 and Congressional trades driving the 9 / 20 insider-conviction score?
• What is the analyst consensus rating and price-target distribution behind the headline targets in the news feed?
• What is the nature of the risk flagged in the Stock Titan item, and how does the 5,713,449,734-share lock-up expiry affect float?